Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes

Clinical Therapeutics

Volumn 37, Issue 12, 2015, Pages 2751-2769

  Turner, Traci ^a   Stein, Evan A ^a  

^a Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

CETP inhibitors; Familial hypercholesterolemia; LDL cholesterol; PCSK9 inhibitors

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE INHIBITOR; ALIROCUMAB; ANACETRAPIB; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; BEMPEDOIC ACID; BOCOCIZUMAB; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EVACETRAPIB; EVINACUMAB; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEGDINETANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DIET THERAPY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SILENCING; GENE THERAPY; HUMAN; MANAGED CARE; MYOSITIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACODYNAMIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RNA INTERFERENCE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VACCINE PRODUCTION; BLOOD; HYPERCHOLESTEROLEMIA;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84951909135     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.09.004     Document Type: Review

References (93)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
2. C. Baigent, A. Keech, P.M. Kearney, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
4. E.S. Stroes, P.D. Thompson, A. Corsini, and et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J 36 2015 1012 1022
5. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 45
6. W.H. Shrank, J.F. Barlow, and T.A. Brennan New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines JAMA 2015 [Epub ahead of print]
7. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
8. HPS2-THRIVE Colaborative Group M.J. Landray, R. Haynes, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
9. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
10. ACCORD Study Group H.N. Ginsberg, M.B. Elam, and et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
11. D.J. Rader, and J.J. Kastelein Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia Circulation 129 2014 1022 1032
12. M. Abifadel, M. Varret, J.-P. Rabes, and et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
13. T.A. Turner, F.J. Raal, and E.A. Stein Evolving targets of therapy: proprotein convertase subtilisin/kexin 9 inhibition C. Ballantyne, Clinical Lipidology: A Companion to Braunwald's Heart Disease 2nd ed 2014 Elsevier New York 346 357
14. G. Lambert, B. Sjouke, B. Choque, and et al. The PCSK9 decade J Lipid Res 53 2012 2515 2524
15. E.A. Stein, and F. Raal Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9 Annu Rev Med 65 2014 417 431
16. T.A. Lagace, D.E. Curtis, R. Garuti, and et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice J Clin Invest 116 2006 2995 3005
17. E.A. Stein, S. Mellis, G.D. Yancopoulos, and et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
18. C.S. Dias, A.J. Shaywitz, S.M. Wasserman, and et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins J Am Coll Cardiol 60 2012 1888 1898
19. European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), the First PCSK9 Inhibitor To Be Approved in the World, for Treatment of High Cholesterol. http://www.amgen.com/media/media-pr-detail.jsp?releaseID=2069405&. Accessed 2015.
20. FDA approves Praluent to treat certain patients with high cholesterol. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm455883.htm. Accessed 2015.
21. C.M. Ballantyne, J. Neutel, A. Cropp, and et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia Am J Cardiol 115 2015 1212 1221
22. N.R. Budha, M. Leabman, J.Y. Jin, and et al. Modeling and simulation to support phase 2 dose selection for RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 Aaps J 17 2015 881 890
23. J. Kastelein, S. Nissen, D. Rader, and et al. Safety and efficacy of Ly3015014, a new monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (Pcsk9) with an inherently longer duration of action, in patients with primary hypercholesterolemia: a randomized, placebo-controlled, dose-ranging, phase 2 study J Am Coll Cardiol 65 2015 A1591 Abstract
24. E.M. Roth, J.M. McKenney, C. Hanotin, and et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
25. E.A. Stein, D. Gipe, J. Bergeron, and et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
26. J.M. McKenney, M.J. Koren, D.J. Kereiakes, and et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
27. E.A. Stein, R.P. Giugliano, M.J. Koren, and et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Eur Heart J 35 2014 2249 2259
28. F. Raal, R. Scott, R. Somaratne, and et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
29. D. Sullivan, A.G. Olsson, R. Scott, and et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 308 2012 2497 2506
30. R.P. Giugliano, N.R. Desai, P. Kohli, and et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
31. M.J. Koren, R. Scott, J.B. Kim, and et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
32. E. Stroes, D. Colquhoun, D. Sullivan, and et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled Phase III clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
33. F.J. Raal, N. Honarpour, D.J. Blom, and et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 385 2015 341 350
34. D.J. Blom, T. Hala, M. Bolognese, and et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
35. J.G. Robinson, B.S. Nedergaard, W.J. Rogers, and et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 2014 1870 1883
36. J.J. Kastelein Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia (heFH) not adequately controlled with current lipid-lowering therapy: Results of ODYSSEY FH I and FH II studies Presented at European Society of Cardiology Congress 2014 Barcelona Spain
37. J.J. Kastelein, J.G. Robinson, M. Farnier, and et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies Cardiovasc Drugs Ther 28 2014 281 289
38. J.G. Robinson, M. Farnier, M. Krempf, and et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
39. M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, and et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1500 1509
40. W.C. Roberts The rule of 5 and the rule of 7 in lipid-lowering by statin drugs Am J Cardiol 80 1997 106 107
41. P.M. Moriarty, T.A. Jacobson, E. Bruckert, and et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial J Clin Lipidol 8 2014 554 561
42. Moriarty PM. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Presented at AHA Scientific Sessions; 2014; Chicago, Ill.
43. F.J. Raal, E.A. Stein, R. Dufour, and et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 385 2015 331 340
44. E.A. Stein, N. Honarpour, S.M. Wasserman, and et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
45. F.J. Raal, R.P. Giugliano, M.S. Sabatine, and et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials J Am Coll Cardiol 63 2014 1278 1288
46. D. Gaudet, D.J. Kereiakes, J.M. McKenney, and et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) Am J Cardiol 114 2014 711 715
47. S. Kathiresan Myocardial Infarction Genetics Consortium. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction N Engl J Med 358 2008 2299 2300
48. Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace, and et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523
49. A.J. Hooper, A.D. Marais, D.M. Tanyanyiwa, and J.R. Burnett The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 193 2007 445 448
50. B. Cariou, K. Ouguerram, Y. Zair, and et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia Arterioscler Thromb Vasc Biol 29 2009 2191 2197
51. J.J. Kastelein, S.I. van Leuven, L. Burgess, and et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
52. TM (Evolocumab) in Patients with High Cholesterol and Clinically Evident Cardiovascular Disease. http://www.prnewswire.com/news-releases/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-patients-with-high-cholesterol-and-clinically-evident-cardiovascular-disease-300094614.html. Accessed 5, 2015.
53. G.G. Schwartz, L. Bessac, L.G. Berdan, and et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial Am Heart J 168 2014 682 689
54. T. Mitchell, G. Chao, D. Sitkoff, and et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering J Pharmacol Exp Ther 350 2014 412 424
55. E.A. Stein, S. Kasichayanula, T. Turner, and et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study J Am Coll Cardiol 2014 63
56. M. Stevenson Therapeutic potential of RNA interference N Engl J Med 351 2004 1772 1777
57. K. Fitzgerald, M. Frank-Kamenetsky, S. Shulga-Morskaya, and et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60 68
58. K.G. Rajeev, J.K. Nair, M. Jayaraman, and et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo Chembiochem 16 2015 903 908
59. G. Galabova, S. Brunner, G. Winsauer, and et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management PLoS One 9 2014 e114469
60. P.J. Barter, H.B. Brewer Jr, M.J. Chapman, and et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2003 160 167
61. A.H. Mohammadpour, and F. Akhlaghi Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective Clin Pharmacokinet 52 2013 615 626
62. P.J. Barter, S.J. Nicholls, J.J.P. Kastelein, and K.-A. Rye Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP inhibition as a strategy to reduce cardiovascular risk: The Pro Case Circulation 132 2015 423 432
63. G.K. Hovingh, K.K. Ray, and S.M. Boekholdt Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: suspension of disbelief? Circulation 132 2015 433 440
64. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
65. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
66. H.M. Dansky, D. Bloomfield, P. Gibbons, and et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia Am Heart J 162 2011 708 716
67. C.P. Cannon, S. Shah, H.M. Dansky, and et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
68. J.J.P. Kastelein, J. Besseling, S. Shah, and et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study Lancet 385 2015 2153 2161
69. Lilly Provides Update on Evacetrapib Phase 3 Trial https://investor.lilly.com/releasedetail.cfm?ReleaseID=923885. Accessed 2015.
70. G.K. Hovingh, J.J.P. Kastelein, S.J.H. van Deventer, and et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial Lancet 386 2015 452 460
71. Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension. http://investor.esperion.com/releasedetail.cfm?ReleaseID=924113. Accessed 2015.
72. S.L. Pinkosky, S. Filippov, R.A. Srivastava, and et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism J Lipid Res 54 2013 134 151
73. P.D. Thompson, J. Rubino, M.J. Janik, and et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance J Clin Lipidol 9 2015 295 304
74. P. Thompson, C. Ballantyne, J. McKenney, and et al. ETC-1002 lowers LDL-C more than ezetimibe in patients with hypercholesterolemia with or without statin intolerance and has a similar safety and tolerability profile J Am Coll Cardiol 65 2015 A1349 [Abstract]
75. J.M. McKenney, J.D. Proctor, S. Harris, and V.M. Chinchili A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients JAMA 271 1994 672 677
76. M.H. Luria EFfect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio Arch Intern Med 148 1988 2493 2495
77. Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
78. P. Canner, K.G. Berge, N.K. Wenger, and et al. Fifteen year mortality in Coronary Drug Project Patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
79. L. Chen, W.Y. So, S.Y. Li, and et al. Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets Mol Cell Endocrinol 404 2015 56 66
80. J.D. Horton, N.A. Shah, J.A. Warrington, and et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes Proc Natl Acad Sci U S A 100 2003 12027 12032
81. J.M. Donovan, M. Mancini, C. Sanabria, and M. Jirousek Phase 1 study of CAT-2054, an oral novel modulator of SREBP J Clin Lipidol 9 2015 474 475
82. Catabasis Pharmaceuticals Announces Positive Top-line Phase 1 Data for Hypercholesterolemia Product Candidate CAT-2054 [press release]. http://www.catabasis.com/pdfs/Catabasis-CAT-2054-101%20results%20final%2013august2015.pdf. Accessed 2015.
83. C. Benedict A novel niacin analogue (ARI-3037MO) induces favorable plasma lipid changes without flush in single and multiple ascending dose placebo controlled trials in normal healthy volunteers Circulation 126 2012 A9595 Abstract
84. F.A. Monsalve, R.D. Pyarasani, F. Delgado-Lopez, and R. Moore-Carrasco Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases Mediators Inflamm 2013 2013 549627
85. H.E. Bays, S. Schwartz, T. Littlejohn 3rd, and et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin J Clin Endocrinol Metab 96 2011 2889 2897
86. Y.J. Choi, B.K. Roberts, X. Wang, and et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia Atherosclerosis 220 2012 470 476
87. CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia [press release]. http://www.marketwatch.com/story/cymabay-therapeutics-announces-preclinical-data-demonstrating-the-potential-of-mbx-8025-to-treat-homozygous-familial-hypercholesterolemia-2015-01-28-8173233. Accessed 2015.
88. C. Bisgaier, A.D. Essenbrug, B.C. Barnett, and et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor J Lipid Res 39 1998 17 30
89. H.E. Bays, J.M. McKenney, C.A. Dujovne, and et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol Am J Cardiol 92 2003 538 543
90. M. Arca, I. Minicocci, and M. Maranghi The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism Curr Opin Lipidol 24 2013 313 320
91. V. Gusarova, C.A. Alexa, Y. Wang, and et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys J Lipid Res 56 2015 1308
92. Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx [press release]. http://www.prnewswire.com/news-releases/isis-pharmaceuticals-reports-positive-phase-1-data-on-isis-angptl3-rx-300053962.html. Accessed 2015.
93. Alnylam Pharmaceuticals. A Subcutaneous Platform for RNAi Therapeutics Targeting Metabolic Diseases: PCSK9 and ANGPTL3. Poster presented at AHA Scientific Sessions; 2014; Chicago, Ill.